Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
MAT1
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "MAT1" in MCE Product Catalog:
17
17 Publications Verification
YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status [1].
17
17 Publications Verification
YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status [1].
1
Target:
Cat. No.: HY-RS20986
Target:
Research Areas:
Mat1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mat1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-E70689
CDK7/CycH/MAT1 Recombinant Human Active Protein Kinase acts as a cyclin-dependent kinase activating kinase. CDK7 exists in several forms including a core tri-partite CDK7/CycH/MAT1 complex known as CAK (cyclin-dependent kinase activating kinase), as a component in the general transcription factor TFIIH and as a component of larger complexes containing pol II and other transcription factors [1].
Cat. No.: HY-RS08166
Target:
Research Areas:
MAT1A Human Pre-designed siRNA Set A contains three designed siRNAs for MAT1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS27503
Target:
Research Areas:
Mat1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Mat1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08566
Target:
Research Areas:
MNAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MNAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-183073
Research Areas:
TZ1104 is a PROTAC-based CDK7 degrader, with a DC50 of 0.88 nM. TZ1104 forms a ternary complex with VHL E3 ligase and CDK7 to trigger proteasome-dependent CDK7 degradation, destabilizing the CDK7-cyclin H-MAT1 complex. TZ1104 suppresses phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. TZ1104 activates the p53-p21 axis and suppresses oncogenic Myc signaling. TZ1104 induces cell cycle arrest, apoptosis, and differentiation of acute leukemia cells. TZ1104 can be used for the research of acute leukemia [1].
Cat. No.: HY-RS00586
Target:
Research Areas:
ALG1 Human Pre-designed siRNA Set A contains three designed siRNAs for ALG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10309
Target:
Research Areas:
PEA15 Human Pre-designed siRNA Set A contains three designed siRNAs for PEA15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-183070
CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 of 0.88 nM. CXJ2080 recruits VHL E3 ligase to induce ubiquitin-proteasome-dependent CDK7 degradation, disrupts the CDK7-cyclin H-MAT1 complex, suppresses CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. CXJ2080 activates the p53-p21 axis, suppresses MYC-driven signaling, induces leukemia cell cycle arrest, apoptosis, and differentiation, reduces CD117 expression, spares platelets and normal PBMCs, maintains sustained CDK7 degradation post-washout. CXJ2080 can be used for the research of acute leukemia [1].
Cat. No.: HY-P701371
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK7; CCNH; MNAT1; Cyclin-dependent kinase 7; 39 kDa protein kinase; p39 Mo15; CDK-activating kinase 1; Cell division protein kinase 7; Serine/threonine-protein kinase 1; TFIIH basal transcription factor complex kinase subunit; Cyclin-H; MO15-associated protein; p34; p37; CDK-activating kinase assembly factor MAT1; CDK7/cyclin-H assembly factor; Cyclin-G1-interacting protein; Menage a trois; RING finger protein 66; RING finger protein MAT1; p35; p36
Species:
Source:
Cat. No.: HY-RS18829
Target:
Research Areas:
Mnat1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mnat1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P704383
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: AdoMet synthase 1; Methionine adenosyltransferase 1(MAT 1); Methionine adenosyltransferase I/III(MAT-I/III)
Cat. No.: HY-P84185A
Synonyms: MAT; SAMS; MATA1; SAMS1; MAT1A
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
